Completed PHASE1 INTERVENTIONAL 1-arm NCT00325013

Evaluation of DHA for the Treatment of PSC

Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)

Sponsor: Beth Israel Deaconess Medical Center

Conditions Colitis Primary Sclerosing Cholangitis

Interventions Docosahexaenoic Acid (DHA)

Updated 5 times since 2017 Last updated: Mar 10, 2015 Started: Dec 31, 2005 Primary completion: May 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00325013, this PHASE1 trial focuses on Colitis and Primary Sclerosing Cholangitis and remains completed. Sponsored by Beth Israel Deaconess Medical Center, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Rochester, United States